Reuter U, Goadsby P, Lanteri-Minet M, et al. Efficacy and safety of erenumab in episodic migraine patients with 2-4 prior preventive treatment failures: Results from the Phase 3b LIBERTY study. AAN 2018, emerging science abstract 009.
‘Antisense’-oligonucleotide HTTRx verlaagt concentratie gemuteerd huntingtine
sep 2019 | Bewegingsstoornissen